EpimAb Biotherapeutics, Inc.

📍 Shanghai, China🗓 Founded 2015👥 41 employees💰 Last funded Apr 2017
Biotechnology🌐 epimab.com
Website LinkedIn
EpimAb Biotherapeutics, Inc., is a China-based, privately held, start-up company founded in 2015 that is developing a portfolio of novel bi-specific antibodies in oncology and immune-oncology. All bispecifics are based on a proprietary platform, FIT-Ig (Fabs in Tandem). Multiple FIT-Igs have already been successfully generated binding to small, large, soluble or membrane-bound antigens with biochemical and biophysical properties similar to their parent monospecific antibodies. The first molecule, EMB-01, is a cMET/EGFR-inhibitor, that is in CMC development in collaboration with WuXi Apptec. EpimAb also has concluded licensing arrangements, e.g. with Kymab and Innovent Biologics, and is open to further partnerships. EpimAb has successfully concluded a Series A round of $25 MM with a consortium of international investors.
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2015
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
1
China
1
Frequently asked questions
Who invested in EpimAb Biotherapeutics, Inc.?
EpimAb Biotherapeutics, Inc. has 2 investors on record on gritt.io, including 2 early-stage backers.
When did EpimAb Biotherapeutics, Inc. last raise funding?
The most recent investment in EpimAb Biotherapeutics, Inc. recorded on gritt.io was in April 2017.
When was EpimAb Biotherapeutics, Inc. founded?
EpimAb Biotherapeutics, Inc. was founded in 2015.
What industry is EpimAb Biotherapeutics, Inc. in?
EpimAb Biotherapeutics, Inc. operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is EpimAb Biotherapeutics, Inc. based?
EpimAb Biotherapeutics, Inc. is headquartered in Shanghai, China.